Inhibitory receptors, such as PD1 and LAG3, synergize to exert critical cell intrinsic control of T cell function, but also contribute to the development, homeostasis and function of regulatory T cells (Tregs). Inhibitory receptors are highly expressed on exhausted tumor-infiltrating lymphocytes (TILs), rendering PD1 and LAG3 barriers to effective anti-tumor immunity. We have shown that combinatorial PD1/LAG3 targeted immunotherapy induces almost complete remission in mice with pre-existing tumors.
AIM 1 : What is the relative and synergistic contributions of PD1 and LAG3 in preventing effective anti- tumor immunity by CD8+ T cells? We hypothesize that ?PD1 and LAG3 synergize to have a dominant effect on CD8+ TILs, thereby mediating tumor-induced tolerance?. We will use CD8+-restricted Cre-mediated PD1/LAG3 deletion to assess their relative and mechanistic contribution to tumor-induced CD8+ T cell exhaustion, using transplantable and genetically-induced models of human cancer, especially melanoma.
AIM 2 : What is the contribution of PD1 and LAG3 in modulating intratumoral Treg function? We hypothesize that ?PD1 and LAG3 limit Treg function but enforce stability in the tumor microenvironment?. We will determine if PD1/LAG3 contribute to Treg function in the tumor microenvironment using mice with restricted PD1/LAG3 deletion in Tregs. PPG Interactions: Project 2 will collaborate with Project 1 to determine if inhibitory receptor loss in tumor- bearing mice induces an autoimmune insult, and Project 3 to compare T cell exhaustion induced by tumors and chronic viral infections. In all Aims, Project 2 will utilize Core B to obtain mice, Core A to obtain statistical support, Core C for transcriptional analysis, and Core D for immunohistological analysis.
The inhibitory receptors PD1 and LAG3 synergize to limit autoimmune disease. However, they are highly expressed on intratumoral T cells and thus limit effective anti-tumor immunity. Although PD1 and LAG3 are now major therapeutic targets, it is not clear how they mediated this synergistic regulation and on which cells types. A greater understanding of these issues could lead to move effective therapeutic strategies.
| Overacre-Delgoffe, Abigail E; Vignali, Dario A A (2018) Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 6:882-887 |
| Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156 |
| Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5 |
| Ratay, Michelle L; Glowacki, Andrew J; Balmert, Stephen C et al. (2017) Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release 258:208-217 |
| Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65 |
| Hope, Jennifer L; Stairiker, Christopher J; Spantidea, Panagiota I et al. (2017) The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1. Front Immunol 8:1696 |
| Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96 |
| Chen, Zeyu; Stelekati, Erietta; Kurachi, Makoto et al. (2017) miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep 20:2584-2597 |
| Zhang, Qianxia; Chikina, Maria; Szymczak-Workman, Andrea L et al. (2017) LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol 2: |
| Kurachi, Makoto; Kurachi, Junko; Chen, Zeyu et al. (2017) Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat Protoc 12:1980-1998 |
Showing the most recent 10 out of 21 publications
